Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐Analysis

Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID‐19) and its complications. We conducted a systematic review and meta‐analysis to describe the current evidence.

[1]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[2]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[3]  Amit N. Patel,et al.  Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[4]  G. Chatellier,et al.  Anakinra for severe forms of COVID-19: a cohort study , 2020, The Lancet Rheumatology.

[5]  C. White,et al.  Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19 , 2020, Annals of Internal Medicine.

[6]  Sindhu R. Johnson,et al.  Hydroxychloroquine shortages during the COVID-19 pandemic , 2020, Annals of the Rheumatic Diseases.

[7]  J. Fallowfield,et al.  Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study , 2020, Gut.

[8]  T. Bove,et al.  Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care , 2020, Journal of Clinical Virology.

[9]  P. Ravaud,et al.  Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data , 2020, BMJ.

[10]  J. Qu,et al.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial , 2020, BMJ.

[11]  David R. Holtgrave,et al.  Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State , 2020, The Journal of Emergency Medicine.

[12]  Sang-Bum Hong,et al.  Re: Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19 , 2020, Journal of Infection.

[13]  A. Zangrillo,et al.  Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study , 2020, The Lancet Rheumatology.

[14]  G. Hripcsak,et al.  Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 , 2020, The New England journal of medicine.

[15]  J. Badie,et al.  Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients , 2020, Médecine et Maladies Infectieuses.

[16]  Rachel M. Kenney,et al.  Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19 , 2020, medRxiv.

[17]  E. Bergot,et al.  Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series , 2020, Annals of the Rheumatic Diseases.

[18]  D. Raoult,et al.  Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France , 2020, Travel Medicine and Infectious Disease.

[19]  A. Omrani,et al.  Tocilizumab for the treatment of severe coronavirus disease 2019 , 2020, Journal of medical virology.

[20]  H. Shan,et al.  Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19 , 2020, medRxiv.

[21]  J. Mallat,et al.  Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study , 2020, medRxiv.

[22]  S. Baldovino,et al.  Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. , 2020 .

[23]  D. Wang,et al.  Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19 , 2020, medRxiv.

[24]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[25]  Stanley B. Cohen,et al.  American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 1 , 2020, Arthritis & rheumatology.

[26]  Baoju Wang,et al.  A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia , 2020, Signal Transduction and Targeted Therapy.

[27]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[28]  Reem A Mustafa,et al.  Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  C. Morélot-Panzini,et al.  Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine , 2020, Annals of the Rheumatic Diseases.

[30]  Jun Li,et al.  No Clear Benefit to the Use of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019 : A Retrospective Cohort Study , 2020, medRxiv.

[31]  E. Shirali,et al.  COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes , 2020, medRxiv.

[32]  E. Nicastri,et al.  Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact , 2020, Journal of Infection.

[33]  A. Vallée,et al.  Interleukin-6 blockade for severe COVID-19 , 2020, medRxiv.

[34]  J. Hardin,et al.  Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19 , 2020, Med.

[35]  A. Sestokas,et al.  Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in Coronavirus Disease 2019: Experience with 32 Patients , 2020, ASAIO journal.

[36]  Carl H. June,et al.  Cytokine release syndrome in severe COVID-19 , 2020, Science.

[37]  M. Konig,et al.  Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist , 2020, Annals of the Rheumatic Diseases.

[38]  J. Chan,et al.  Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study , 2020, medRxiv.

[39]  V. Negi,et al.  A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease‐19 (COVID‐19) , 2020, International journal of rheumatic diseases.

[40]  H. Shan,et al.  Key to successful treatment of COVID-19: accurate identification of severe risks and early intervention of disease progression , 2020, medRxiv.

[41]  Yongsheng Li,et al.  Adjuvant corticosteroid therapy for critically ill patients with COVID-19 , 2020, Critical Care.

[42]  A. Pan,et al.  Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19 , 2020, Journal of Infection.

[43]  Matthew Rowland,et al.  Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed , 2020, The Lancet.

[44]  Dong Liu,et al.  Tocilizumab treatment in COVID‐19: A single center experience , 2020, Journal of medical virology.

[45]  Jonathan H. Morgan,et al.  Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support , 2020, medRxiv.

[46]  Q. Bassat,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[47]  P. Marchetti,et al.  Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. , 2020, European review for medical and pharmacological sciences.

[48]  Duanqing Pei,et al.  Treating COVID-19 with Chloroquine , 2020, Journal of molecular cell biology.

[49]  Zhan Zhang,et al.  Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.

[50]  C. Delaugerre,et al.  No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection , 2020, Médecine et Maladies Infectieuses.

[51]  R. Grainger,et al.  A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 , 2020, Annals of Internal Medicine.

[52]  Giuseppe Citerio,et al.  Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) , 2020, Intensive Care Medicine.

[53]  A. Davis,et al.  Management of Critically Ill Adults With COVID-19. , 2020, JAMA.

[54]  H. Wunsch,et al.  Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) , 2020, Critical care medicine.

[55]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[56]  Zhìhóng Hú,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[57]  W. Tu,et al.  Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[59]  Jiarui Feng,et al.  Clinical characteristics of 101 COVID-19 nonsurvivors in Wuhan, China: a retrospective study , 2020, medRxiv.

[60]  Zhiyong Ma,et al.  Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients , 2020, medRxiv.

[61]  Alexis Jacquier,et al.  Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study , 2020, Travel Medicine and Infectious Disease.

[62]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[63]  Yixiao Lin,et al.  Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients , 2020, Chinese medical journal.

[64]  Eculizumab (Soliris) in Covid-19 Infected Patients , 2020, Case Medical Research.

[65]  Wenwu Sun,et al.  Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019 , 2020, medRxiv.

[66]  A. Phelan,et al.  Baricitinib as potential treatment for 2019-nCoV acute respiratory disease , 2020, The Lancet.

[67]  V. Welch,et al.  Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline , 2020, BMJ.

[68]  Zhifeng Liu,et al.  Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study , 2020, medRxiv.

[69]  SEPSIS BULLETIN,et al.  Surviving Sepsis Campaign : Guidelines on the Management of Critically Ill Adults with Coronavirus Disease , 2020 .

[70]  Joanne E McKenzie,et al.  Synthesizing and presenting findings using other methods , 2019, Cochrane Handbook for Systematic Reviews of Interventions.

[71]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[72]  Carrie D. Patnode,et al.  Recommendations for assessing the risk of bias in systematic reviews of health-care interventions. , 2017, Journal of clinical epidemiology.

[73]  D. Pieper,et al.  Clarifying the distinction between case series and cohort studies in systematic reviews of comparative studies: potential impact on body of evidence and workload , 2017, BMC Medical Research Methodology.

[74]  Emily Newman,et al.  PROSPERO International prospective register of systematic reviews , 2017 .

[75]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[76]  D. Altman,et al.  Distinguishing Case Series From Cohort Studies , 2012, Annals of Internal Medicine.

[77]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[78]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[79]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[80]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.

[81]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.